Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab

OncoImmunology

Volumn 6, Issue 12, 2017, Pages

  Reuben, Alexandre ^a   Petaccia de Macedo, Mariana ^a,e   McQuade, Jennifer ^a   Joon, Aron ^a   Ren, Zhiyong ^a,c   Calderone, Tiffany ^a   Conner, Brandy ^a   Wani, Khalida ^a   Cooper, Zachary A ^a,d   Tawbi, Hussein ^a   Tetzlaff, Michael T ^a   Padera, Robert F ^b   Durand, Jean Bernard ^a   Lazar, Alexander J ^a   Wargo, Jennifer A ^a   Davies, Michael A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c AtlantiCare   (United States)

^d MEDIMMUNE   (United States)

^e A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Ipilimumab; Melanoma; Myocarditis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BRAIN NATRIURETIC PEPTIDE; CD68 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CORTICOSTEROID; CREATINE KINASE MB; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; DEXAMETHASONE; IPILIMUMAB; T LYMPHOCYTE RECEPTOR; TROPONIN I;

ARTICLE; AUTOIMMUNITY; B CELL LYMPHOMA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHEMILUMINESCENCE IMMUNOASSAY; DIASTOLIC DYSFUNCTION; DYSPNEA; ELECTROCARDIOGRAPHY; FATIGUE; GENE EXPRESSION; GENETIC TRANSCRIPTION; GIANT CELL; GLEASON SCORE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE PERFUSION; HEART TISSUE; HEART VENTRICLE FIBRILLATION; HEPATITIS; HEPATOMEGALY; HISTOLOGY; HOSPITAL DISCHARGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TECHNIQUE; IMMUNOTHERAPY; LUNG METASTASIS; LUNG NODULE; LYMPHADENOPATHY; LYMPHOCYTIC INFILTRATION; MALE; METASTATIC MELANOMA; MYOCARDITIS; PLEURA EFFUSION; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; ST SEGMENT ELEVATION; TRANSTHORACIC ECHOCARDIOGRAPHY; X-RAY COMPUTED TOMOGRAPHY;

EID: 85028562967     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1361097     Document Type: Article

References (21)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23. doi:10.1056/NEJMoa1003466. PMID:20525992
2. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled Analysis of long-term survival data from phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889-94. doi:10.1200/JCO.2014.56.2736. PMID:25667295
3. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-26. doi:10.1056/NEJMoa1104621. PMID:21639810
4. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522-30. doi:10.1016/S1470-2045(15)70122-1. PMID:25840693
5. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 2016;6:827-37. doi:10.1158/2159-8290.CD-15-1545. PMID:27301722
6. Cooper ZA, Frederick DT, Juneja VR, Sullivan RJ, Lawrence DP, Piris A, Sharpe AH, Fisher DE, Flaherty KT, Wargo JA. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology. 2013;2:e26615. doi:10.4161/onci.26615. PMID:24251082
7. Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016;4:50. doi:10.1186/s40425-016-0152-y. PMID:27532025
8. Laubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer. 2015;3:11. doi:10.1186/s40425-015-0057-1. PMID:25901283
9. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749-55. doi:10.1056/NEJMoa1609214. PMID:27806233
10. Geisler BP, Raad RA, Esaian D, Sharon E, Schwartz DR. Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: A case of takotsubo-like syndrome. J Immunother Cancer. 2015;3:4. doi:10.1186/s40425-015-0048-2. PMID:25705383
11. Cheng F, Loscalzo J. Autoimmune cardiotoxicity of cancer immunotherapy. Trends Immunol. 2017;38:77-8. doi:10.1016/j.it.2016.11.007. PMID:27919707
12. Heinzerling L, Goldinger SM. A review of serious adverse effects under treatment with checkpoint inhibitors. Curr Opin Oncol. 2017;29:136-44. doi:10.1097/CCO.0000000000000358. PMID:28059853
13. Kandolin R, Lehtonen J, Salmenkivi K, Raisanen-Sokolowski A, Lommi J, Kupari M. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail. 2013;6:15-22. doi:10.1161/CIRCHEARTFAILURE.112.969261. PMID:23149495
14. Xu J, Brooks EG. Giant cell myocarditis: A brief review. Arch Pathol Lab Med. 2016;140:1429-34. doi:10.5858/arpa.2016-0068-RS. PMID:27922771
15. Koelzer VH, Rothschild SI, Zihler D, Wicki A, Willi B, Willi N, Voegeli M, Cathomas G, Zippelius A, Mertz KD. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. J Immunother Cancer. 2016;4:13. doi:10.1186/s40425-016-0117-1. PMID:26981243
16. Mehta A, Gupta A, Hannallah F, Koshy T, Reimold S. Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma. Melanoma Res. 2016;26:319-20. doi:10.1097/CMR.0000000000000251. PMID:27110676
17. Cooper LT, Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis–natural history and treatment. Multicenter giant cell myocarditis study group investigators. N Engl J Med. 1997;336:1860-6. doi:10.1056/NEJM199706263362603. PMID:9197214
18. Yuan Z, Shioji K, Kishimoto C. Immunohistological analyses of myocardial infiltrating cells in various animal models of myocarditis. Exp Clin Cardiol. 2003;8:13-6. PMID:19644581
19. Fousteri G, Dave A, Morin B, Omid S, Croft M, von Herrath MG. Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditis. J Autoimmun. 2011;36:210-20. doi:10.1016/j.jaut.2011.01.006. PMID:21333491
20. Hirota Y, Osuga Y, Koga K, Yoshino O, Hirata T, Morimoto C, Harada M, Takemura Y, Nose E, Yano T, et al. The expression and possible roles of chemokine CXCL11 and its receptor CXCR3 in the human endometrium. J Immunol. 2006;177:8813-21. doi:10.4049/jimmunol.177.12.8813. PMID:17142784
21. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, et al. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. npj Genomic Med. 2017;2:10. doi:10.1038/s41525-017-0013-8